ATE227585T1 - Behandlung mittels eisen-entzug kombiniert mit igg antikörper - Google Patents

Behandlung mittels eisen-entzug kombiniert mit igg antikörper

Info

Publication number
ATE227585T1
ATE227585T1 AT94913873T AT94913873T ATE227585T1 AT E227585 T1 ATE227585 T1 AT E227585T1 AT 94913873 T AT94913873 T AT 94913873T AT 94913873 T AT94913873 T AT 94913873T AT E227585 T1 ATE227585 T1 AT E227585T1
Authority
AT
Austria
Prior art keywords
treatment
igg antibodies
tumor cells
combined
iron
Prior art date
Application number
AT94913873T
Other languages
English (en)
Inventor
John D Kemp
Original Assignee
Univ Iowa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Iowa filed Critical Univ Iowa
Application granted granted Critical
Publication of ATE227585T1 publication Critical patent/ATE227585T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT94913873T 1993-04-29 1994-01-25 Behandlung mittels eisen-entzug kombiniert mit igg antikörper ATE227585T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5467993A 1993-04-29 1993-04-29
PCT/US1994/000911 WO1994025066A1 (en) 1993-04-29 1994-01-25 COMBINED TREATMENT OF IRON DEPLETION AND IgG ANTIBODY

Publications (1)

Publication Number Publication Date
ATE227585T1 true ATE227585T1 (de) 2002-11-15

Family

ID=21992780

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94913873T ATE227585T1 (de) 1993-04-29 1994-01-25 Behandlung mittels eisen-entzug kombiniert mit igg antikörper

Country Status (10)

Country Link
EP (1) EP0697889B1 (de)
JP (1) JPH09500868A (de)
AT (1) ATE227585T1 (de)
AU (1) AU699915B2 (de)
CA (1) CA2161656A1 (de)
DE (1) DE69431717T2 (de)
DK (1) DK0697889T3 (de)
ES (1) ES2187521T3 (de)
PT (1) PT697889E (de)
WO (1) WO1994025066A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2453892B1 (de) * 2009-07-16 2013-05-29 Institut National de la Santé et de la Recherche Medicale Pharmazeutische zusammensetzungen und deren verwendung zur krebstherapie
WO2020127885A1 (en) * 2018-12-21 2020-06-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions for treating cancers and resistant cancers
CN114217071B (zh) * 2021-12-01 2023-11-14 柏荣诊断产品（上海）有限公司 一种高特异性透散射一体法铁蛋白胶乳比浊检测试剂盒

Also Published As

Publication number Publication date
PT697889E (pt) 2003-03-31
DE69431717D1 (de) 2002-12-19
EP0697889B1 (de) 2002-11-13
EP0697889A1 (de) 1996-02-28
WO1994025066A1 (en) 1994-11-10
ES2187521T3 (es) 2003-06-16
AU6586094A (en) 1994-11-21
DK0697889T3 (da) 2003-03-17
EP0697889A4 (de) 1997-01-02
JPH09500868A (ja) 1997-01-28
CA2161656A1 (en) 1994-11-10
DE69431717T2 (de) 2003-09-18
AU699915B2 (en) 1998-12-17

Similar Documents

Publication Publication Date Title
LU91116I2 (en) cetuximab
HUT72914A (en) Monoclonal, chimeric, radiolabeled antibodies to the b cell sorface antigen bp 35 ("cd20"), hybridoma cells producing monoclonal antibodies and application of antibodies for treatment of b cell lymphoma
GB9125768D0 (en) Therapeutic method
ATE70309T1 (de) Menschliche monoklonale antikoerper gegen bakterielle toxine.
DK25084A (da) Human-human hybridoma mod neoplasmer
DE69531290D1 (de) Antigen-besierende heteropolymere zur behandlung von autoimmunkrankheiten mittels diesen
UA50708C2 (uk) Моноклональне антитіло, яке має здатність розпізнавати антиген, який викликає апоптоз мієлоїдних клітин, фрагмент f(ab)2 моноклонального антитіла, гібридома ferm bp-4382
MY106561A (en) Method of making factor-dependent human b cell lines
GR3031518T3 (en) Selective system scan for multizone radiotelephone subscriber units.
MY135673A (en) Monoclonal antibodies for inducing tolerance
DE3684211D1 (de)
YU306680A (en) Method of obtaining monoclonal antibodies
EA199900409A1 (ru) Растворимые рецепторы бета-лимфотоксина, антитела против рецепторов лимфотоксина и антитела против лимфотоксиновых лигандов как терапевтические агенты для лечения иммунологических заболеваний
ATE227585T1 (de) Behandlung mittels eisen-entzug kombiniert mit igg antikörper
DE69015230D1 (de) Antikörper gegen menschliches Sperma, ihre Herstellung und Anwendung.
DE69024871D1 (de) Monoklonaler Antikörper gegen menschliches BCDF und Immuntestverfahren unter dessen Verwendung
DE68924983T2 (de) Anti-idiotyp antikörper induktion eines antitumorenresponses.
DE69434691D1 (de) Zubereitung für übertragung der aktive tumorspezifische immunisierung von einem immunisiertem allogenem knochenmarkspender
ATE274920T1 (de) Verwendung von anti-il-12 antikörpern bei transplantationsabstossungen
DE3689299T2 (de) Verwendung von amphipatischen Molekülen zur Radiodarstellung und Therapie mittels monoklonaler oder polyklonaler Antikörperkonjugate.
WO1987007302A3 (en) MONOCLONAL ANTIBODIES TO HUMAN LYMPHOCYTE IgE RECEPTORS, HYBRIDOMAS PRODUCING SUCH ANTIBODIES, AND KITS FOR USING SUCH ANTIBODIES
FR2621127B1 (fr) Anticorps monoclonal reconnaissant un epitope de la chaine gamma des recepteurs de surface des cellules t humaines, lignee de cellules d'hybridomes produisant cet anticorps, et utilisation de cet anticorps monoclonal
YAGAWA et al. Induction of proliferation and differentiation of murine B cells bearing surface Igλ by rat monoclonal antibody to λ chain
DE69221605T2 (de) Nicht-zellzahlverringernde cd4-spezifische monoklonale antikörper zur behandlung von insulinabhängigem diabetes mellitus (iddm)
SE8401946D0 (sv) Antibody to human prostate cancer

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0697889

Country of ref document: EP

REN Ceased due to non-payment of the annual fee